Healthcare provider profile · identity verified

Markus Sonntag, MD

Internal Medicine · ORANGE PARK, FL · NPI 1942216031

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	536	161
Rosuvastatin Calcium	Rosuvastatin Calcium	425	130
Levothyroxine Sodium	Levothyroxine Sodium	320	93
Amlodipine Besylate	Amlodipine Besylate	288	88
Lisinopril	Lisinopril	246	74
Losartan Potassium	Losartan Potassium	217	67
Omeprazole	Omeprazole	215	66
Metoprolol Succinate	Metoprolol Succinate	161	54
Gabapentin	Gabapentin	157	47
Metformin Hcl Er	Metformin Hcl	140	49
Carvedilol	Carvedilol	139	46
Eliquis	Apixaban	130	36
Metformin Hcl	Metformin Hcl	127	42
Ozempic	Semaglutide	127	23
Pravastatin Sodium	Pravastatin Sodium	119	37
Hydrochlorothiazide	Hydrochlorothiazide	112	33
Sertraline Hcl	Sertraline Hcl	112	33
Tamsulosin Hcl	Tamsulosin Hcl	107	37
Allopurinol	Allopurinol	104	29
Jardiance	Empagliflozin	100	19
Furosemide	Furosemide	95	32
Pantoprazole Sodium	Pantoprazole Sodium	95	32
Pioglitazone Hcl	Pioglitazone Hcl	92	25
Simvastatin	Simvastatin	91	26
Montelukast Sodium	Montelukast Sodium	83	22
Valsartan	Valsartan	77	21
Synthroid	Levothyroxine Sodium	76	22
Ezetimibe	Ezetimibe	72	24
Escitalopram Oxalate	Escitalopram Oxalate	70	25
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	66	13
Chlorthalidone	Chlorthalidone	65	18
Metoprolol Tartrate	Metoprolol Tartrate	64	19
Duloxetine Hcl	Duloxetine Hcl	61	21
Clopidogrel	Clopidogrel Bisulfate	57	17
Mounjaro	Tirzepatide	55	suppressed
Spironolactone	Spironolactone	51	16
Potassium Chloride	Potassium Chloride	49	16
Prednisone	Prednisone	49	32
Xarelto	Rivaroxaban	48	suppressed
Trulicity	Dulaglutide	47	11
Albuterol Sulfate Hfa	Albuterol Sulfate	41	23
Finasteride	Finasteride	41	14
Alendronate Sodium	Alendronate Sodium	40	13
Atenolol	Atenolol	40	14
Fluticasone Propionate	Fluticasone Propionate	40	16
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	40	13
Famotidine	Famotidine	38	11
Glimepiride	Glimepiride	38	12
Propranolol Hcl	Propranolol Hcl	36	13
Rybelsus	Semaglutide	36	suppressed
Glipizide	Glipizide	35	suppressed
Donepezil Hcl	Donepezil Hcl	34	suppressed
Paroxetine Hcl	Paroxetine Hcl	34	suppressed
Azelastine Hcl	Azelastine Hcl	33	14
Celecoxib	Celecoxib	33	13
Alprazolam	Alprazolam	32	14
Torsemide	Torsemide	32	12
Januvia	Sitagliptin Phosphate	28	suppressed
Ketoconazole	Ketoconazole	28	13
Memantine Hcl	Memantine Hcl	28	suppressed
Irbesartan	Irbesartan	27	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	27	suppressed
Citalopram Hbr	Citalopram Hydrobromide	26	suppressed
Meloxicam	Meloxicam	26	suppressed
Ramipril	Ramipril	25	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	25	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	25	suppressed
Cephalexin	Cephalexin	24	22
Eszopiclone	Eszopiclone	24	suppressed
Tramadol Hcl	Tramadol Hcl	24	suppressed
Trazodone Hcl	Trazodone Hcl	24	suppressed
Lorazepam	Lorazepam	23	suppressed
Primidone	Primidone	23	suppressed
Clonazepam	Clonazepam	22	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	22	22
Benazepril Hcl	Benazepril Hcl	21	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	21	suppressed
Telmisartan	Telmisartan	21	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	20	suppressed
Ipratropium Bromide	Ipratropium Bromide	20	suppressed
Entresto	Sacubitril/Valsartan	19	suppressed
Buspirone Hcl	Buspirone Hcl	18	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	18	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	18	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	18	suppressed
Lovastatin	Lovastatin	18	suppressed
Methocarbamol	Methocarbamol	18	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	18	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	16	suppressed
Novolog Flexpen	Insulin Aspart	16	suppressed
Ondansetron Odt	Ondansetron	16	suppressed
Amoxicillin	Amoxicillin	15	11
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	15	14
Pregabalin	Pregabalin	15	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	15	suppressed
Clonidine Hcl	Clonidine Hcl	14	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	14	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	14	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	14	suppressed
Sildenafil Citrate	Sildenafil Citrate	14	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	13	suppressed
Farxiga	Dapagliflozin Propanediol	13	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	13	suppressed
Mupirocin	Mupirocin	13	suppressed
Nitroglycerin	Nitroglycerin	13	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	13	suppressed
Tizanidine Hcl	Tizanidine Hcl	13	suppressed
Enalapril Maleate	Enalapril Maleate	12	suppressed
Nystatin	Nystatin	12	suppressed
Testosterone	Testosterone	12	suppressed
Ursodiol	Ursodiol	12	suppressed
Fluticasone Propionate Hfa	Fluticasone Propionate	11	suppressed
Levetiracetam	Levetiracetam	11	suppressed
Mirtazapine	Mirtazapine	11	suppressed
Propranolol Hcl Er	Propranolol Hcl	11	suppressed
Rivastigmine	Rivastigmine	11	suppressed
Rytary	Carbidopa/Levodopa	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error